Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Chronic Lymphocytic Leukemia | Research article

Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients

Authors: Vu Luan Dang Chi, Soizic Garaud, Pushpamali De Silva, Vincent Thibaud, Basile Stamatopoulos, Mimoune Berehad, Chunyan Gu-Trantien, Mohammad Krayem, Hugues Duvillier, Jean-Nicolas Lodewyckx, Karen Willard-Gallo, Catherine Sibille, Dominique Bron

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Age-related genetic changes in lymphocyte subsets are not currently well documented. BACH2 is a transcription factor that plays an important role in immune-mediated homeostasis by tightly regulating PRDM1 expression in both B-cells and T-cells. BACH2 gene expression is highly sensitive to DNA damage in aged mice. This concept led us to investigate the variation in BACH2 and also PRDM1 expression in major lymphocyte subsets with age.

Methods

Lymphocyte subsets from 60 healthy donors, aged from 20 to 90 years, and 41 untreated chronic lymphocytic leukemia patients were studied. BACH2 and PRDM1 gene expression was analyzed by real-time quantitative PCR. BACH2 gene expression was correlated with its protein expression. Lymphocyte apoptosis was evaluated after intracellular oxidative stress-inducing etoposide treatment of T and B cells.

Results

Our analysis shows BACH2 mRNA downregulation with age in healthy donor CD4+, CD8+ T-cells and CD19+ B-cells. Decreased BACH2 expression was also correlated with an age-related reduction in CD8 + CD28+ T-cells. We found a strong correlation between age-related BACH2 downregulation and decreased CD4+ T-cell and CD19+ B-cell apoptosis. PRDM1, as expected, was significantly upregulated in CD4+ T-cells, CD8+ T-cells and CD19+ B-cells, and inversely correlated with BACH2. A comparison of untreated chronic lymphocytic leukemia patients with age-matched healthy donors reveals that BACH2 mRNA expression was further reduced in CD4+ T-cells, CD8+ T-cells and leukemic-B cells. PRDM1 gene expression was consequently significantly upregulated in CD4+ and CD8+ T-cells in chronic lymphocytic leukemia patients but not in their leukemic B-cells.

Conclusion

Overall, our data suggest that BACH2 and PRDM1 genes are significantly correlated with age in human immune cells and may be involved in immunosenescence.
Appendix
Available only for authorised users
Literature
1.
Bhatia-Dey N, Kanherkar RR, Stair SE, Makarev EO, Csoka AB. Cellular senescence as the causal nexus of aging. Front Genet. 2016;7.
2.
Hoenicke L, Zender L. Immune surveillance of senescent cells—biological significance in cancer-and non-cancer pathologies. Carcinogenesis. 2012;33(6):1123–6.CrossRef
3.
Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohee S, Garaud S, et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI insight. 2017;2(11).
4.
Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med. 2011;11(61):537–50.PubMed
5.
Wong C, Goldstein DR. Impact of aging on antigen presentation cell function of dendritic cells. Curr Opin Immunol. 2013;25(4):535–41.CrossRef
6.
Golomb L, Sagiv A, Pateras IS, Maly A, Krizhanovsky V, Gorgoulis VG, et al. Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy. Cell Death Differ. 2015;22(11):1764–74.CrossRef
7.
Weyand CM, Yang Z, Goronzy JJ. T-cell aging in rheumatoid arthritis. Curr Opin Rheumatol. 2014;26(1):93–100.CrossRef
8.
Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14(5):428–36.CrossRef
9.
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217.CrossRef
10.
Alberti S, Cevenini E, Ostan R, Capri M, Salvioli S, Bucci L, et al. Age-dependent modifications of type 1 and type 2 cytokines within virgin and memory CD4+ T cells in humans. Mech Ageing Dev. 2006;127(6):560–6.CrossRef
11.
Adams AA, Breathnach CC, Katepalli MP, Kohler K, Horohov DW. Advanced age in horses affects divisional history of T cells and inflammatory cytokine production. Mech Ageing Dev. 2008;129(11):656–64.CrossRef
12.
Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44(6):651–8.CrossRef
13.
Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.CrossRef
14.
Baronzio G, Parmar G, Shubina IZ, Cassutti V, Giuli S, Ballerini M, et al. Update on the challenges and recent advances in cancer immunotherapy. ImmunoTargets Ther. 2013;2:39–49.CrossRef
15.
16.
Uittenboogaard LM, Payan-Gomez C, Pothof J, van Ijcken W, Mastroberardino PG, van der Pluijm I, et al. BACH2: a marker of DNA damage and ageing. DNA repair. 2013;12(11):982–92.CrossRef
17.
Sidwell T, Kallies A. Bach2 is required for B cell and T cell memory differentiation. Nat Immunol. 2016;17(7):744–5.CrossRef
18.
Nutt SL, Fairfax KA, Kallies A. BLIMP1 guides the fate of effector B and T cells. Nat Rev Immunol. 2007;7(12):923–7.CrossRef
19.
Tashiro S, Muto A, Tanimoto K, Tsuchiya H, Suzuki H, Hoshino H, et al. Repression of PML nuclear body-associated transcription by oxidative stress-activated Bach2. Mol Cell Biol. 2004;24(8):3473–84.CrossRef
20.
Yoshida C, Yoshida F, Sears DE, Hart SM, Ikebe D, Muto A, et al. Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood. 2007;109(3):1211–9.CrossRef
21.
Muto A, Tashiro S, Tsuchiya H, Kume A, Kanno M, Ito E, et al. Activation of Maf/AP-1 repressor Bach2 by oxidative stress promotes apoptosis and its interaction with promyelocytic leukemia nuclear bodies. J Biol Chem. 2002;277(23):20724–33.CrossRef
22.
23.
24.
Duckworth A, Glenn M, Slupsky JR, Packham G, Kalakonda N. Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy. Blood. 2014;123(21):3277–85.CrossRef
25.
Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313–20.CrossRef
26.
Alter-Wolf S, Blomberg BB, Riley RL. Deviation of the B cell pathway in senescent mice is associated with reduced surrogate light chain expression and altered immature B cell generation, phenotype, and light chain expression. J Immunol. 2009;182(1):138–47.CrossRef
27.
Bron D, Ades L, Fulop T, Goede V. Aging and malignant hemopathies. Haematologica. 2015;100(5):571.CrossRef
28.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRef
29.
Tsukumo S-I, Unno M, Muto A, Takeuchi A, Kometani K, Kurosaki T, et al. Bach2 maintains T cells in a naive state by suppressing effector memory-related genes. Proc Natl Acad Sci. 2013;110(26):10735–40.CrossRef
30.
31.
Andersen MH, Schrama D, Thor Straten P, Becker JC. Cytotoxic T cells. J Investig Dermatol. 2006;126(1):32–41.CrossRef
32.
Sibile C. Genetic and phenotypic characterization of the lymphocytic variant of the Hypereosinophilic Syndrome: a model of T lymphomagenesis. PhD Thesis; 2010.
33.
Kamio T, Toki T, Kanezaki R, Sasaki S, Tandai S, Terui K, et al. B-cell–specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. Blood. 2003;102(9):3317–22.CrossRef
34.
Zhang T, Ma J, Nie K, Yan J, Liu Y, Bacchi C, et al. Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma. Blood Cancer J. 2014;4(11):e261.CrossRef
35.
Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med. 2013;19(8):1014–22.CrossRef
36.
Tanaka H, Muto A, Shima H, Katoh Y, Sax N, Tajima S, et al. Epigenetic Regulation of the Blimp-1 Gene (Prdm1) in B Cells Involves Bach2 and Histone Deacetylase 3. J Biol Chem. 2016;291(12):6316–30.CrossRef
37.
Hangaishi A, Kurokawa M. Blimp-1 is a tumor suppressor gene in lymphoid malignancies. Int J Hematol. 2010;91(1):46–53.CrossRef
38.
Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006;203(2):311–7.CrossRef
39.
Ravoet M, Sibille C, Roufosse F, Duvillier H, Sotiriou C, Schandené L, et al. 6q-is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica. 2005;90(6):753–65.PubMed
40.
Ravoet M, Sibille C, Gu C, Libin M, Haibe-Kains B, Sotiriou C, et al. Molecular profiling of CD3− CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood. 2009;114(14):2969–83.CrossRef
41.
Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med. 1992;176(5):1319–26.CrossRef
Metadata
Title
Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients
Authors
Vu Luan Dang Chi
Soizic Garaud
Pushpamali De Silva
Vincent Thibaud
Basile Stamatopoulos
Mimoune Berehad
Chunyan Gu-Trantien
Mohammad Krayem
Hugues Duvillier
Jean-Nicolas Lodewyckx
Karen Willard-Gallo
Catherine Sibille
Dominique Bron
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5276-2

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Case report

Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature

Research article

Obesity impacts the regulation of miR-10b and its targets in primary breast tumors

Research article

A case of intraplacental gestational choriocarcinoma; characterised by the methylation pattern of the early placenta and an absence of driver mutations

Research article

Increased PHGDH expression promotes aberrant melanin accumulation

Research article

Measuring the impact of oesophagectomy on physical functioning and physical activity participation: a prospective study

Research article

Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits